| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA806: Belimumab for treating lupus nephritis (terminated appraisal) |
|
Medicine details |
|
| Medicine name | belimumab (Benlysta®) |
| Formulation | 120 mg, 400 mg powder for concentrate for solution for infusion |
| Reference number | 4235 |
| Indication | In combination with background immunosuppressive therapies for the treatment of adult patients with active lupus nephritis |
| Company | GlaxoSmithKline UK |
| BNF chapter | Musculoskeletal & joint diseases |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 15/06/2021 |
| NICE guidance | TA806: Belimumab for treating lupus nephritis (terminated appraisal) |